Provides an update on Pre-Rolls and new
Product Development
WINNIPEG, Sept. 2, 2019 /CNW/ - DELTA 9 CANNABIS INC. (TSX:
DN) (OTCQX: VRNDF) ("Delta 9" or the "Company"), is pleased to
announce that on August 30, 2019 it
received its renewal license from Health Canada for a term of three
years. This license authorizes Delta 9 to cultivate, process and
sell cannabis from its Winnipeg
production facility. The Company is also pleased to provide
investors with an update on cannabis oils sales, cannabis pre-rolls
sales, and new product development.
Health Canada License Renewal and Oils Sales
Authorization
The Company, through its subsidiary, Delta 9 Bio-Tech Inc., has
received its renewed Standard Cultivation and Standard Processing
license for cannabis from Health Canada. The Company has fulfilled
Health Canada's rigorous specifications, and successfully passed
all inspections.
"Delta 9 employees have worked hard to meet the requirements
within Health Canada's strictly regulated licensing environment. It
speaks to the professionalism of our team that it has maintained
the high standards of safety, quality and security in accordance
with Health Canada's regulations for licensed producers," said
John Arbuthnot, Chief Executive
Officer of Delta 9.
The Company has also received approval from Health Canada for
sales of cannabis oil products. The Company has already completed
production of several initial batches of its "Odyssey"
and "Oasis" lines of ingestible oils and will proceed with
sales of these products in the medical and recreational use
cannabis markets.
Pre-Rolls
In June this year the Company launched its "Bliss" line
of pre-rolled cannabis products, which consist of blended cannabis
flower, rolled in a cigarette format, or "joint", for sale in the
medical and recreational use cannabis markets. To date the Company
has produced and sold over 75,000 cannabis pre-rolls.
"It is management's belief that these products will become an
increasingly important component of the medical and recreational
use cannabis markets in the future," said John Arbuthnot, Chief Executive Officer of Delta
9. "A continually expanding line of high-quality cannabis products
is a major goal for the Company over this year and this is the
first of what we hope are several milestones in our progress."
Products for Future Development
Nanosphere Evolve Products
Delta 9 has acquired an exclusive license in Canada to manufacture and sell products made
with the patented technology of Nanosphere Health Sciences Inc.
("NanoSphere") for the delivery of cannabinoids via nanoparticle
technology. The two companies are in the process of developing the
first product for Canada; an
intraoral cannabis oil containing cannabinoid nanoparticles.
The NanoSphere delivery system for cannabis works by
nano-encapsulating active ingredients in phospholipid membranes for
transportation through the skin and mucosa into the bloodstream
within minutes. Cannabis applications of the technology include
transdermal viscous gels, intranasal products and intraoral
products, all of which provide rapid results, precise dosages and
high bioavailability. The NanoSphere delivery system of cannabis
can eliminate the need for inhalation or ingestion of cannabis,
offering users a potentially safer and more effective method of
consumption.
Dried Sift Cannabis
The Company is currently developing its "Sapphire" line
of dried sift cannabis products for the recreational cannabis
market which involves sifting the Company's blended products and
refining them, leaving more of the high potency resin glands and
less of the low potency plant material. The final product is a
yellow/brownish powder and has a potency that is up to triple that
of the whole flower dried cannabis materials. The Company plans to
release dried sift products in the recreational cannabis market in
the third quarter of 2019. Management expects that retail pricing
for these products will be up to $30
per gram.
Oils, Extracts, and Derivative Products
The Company continues to develop and expand its in-house oils
production capacity and is working with partners regarding its
strategy for new cannabis extracts and derivative products once the
federal government finalizes its expanded extract regulations,
which are expected to become effective in 2019.
About Delta 9 Cannabis Inc.
Delta 9 Cannabis Inc. is a vertically integrated cannabis
company focused on bringing the highest quality cannabis products
to market. Delta 9's wholly-owned subsidiary, Delta 9 Bio-Tech
Inc., is a licensed producer of medical and recreational cannabis
and operates an 80,000 square foot production facility
in Winnipeg, Manitoba,
Canada. Delta 9 owns and operates a chain of retail stores
under the Delta 9 Cannabis Store brand. Delta 9's shares trade on
the Toronto Stock Exchange under the symbol "DN" and on the OTCQX
under the symbol VRNDF. For more information, please visit
www.delta9.ca.
Disclaimer for Forward-Looking Information
Certain statements in this release are forward-looking
statements, which reflect the expectations of management regarding
the Company's future business plans and other matters.
Forward-looking statements consist of statements that are not
purely historical, including any statements regarding beliefs,
plans, expectations or intentions regarding the future. Forward
looking statements in this news release include statements relating
to: (i) Delta 9's plans to expand its cannabis product
offerings; and (ii) Health Canada approvals for certain cannabis
products. Such statements are subject to risks and
uncertainties that may cause actual results, performance or
developments to differ materially from those contained in the
statements, including failure to receive all necessary
approvals for new cannabis product offerings or new cannabis
product offerings not being developed by Delta 9, as well as
all risk factors set forth in the annual information form of Delta
9 dated April 30, 2019 which has been filed on SEDAR. No
assurance can be given that any of the events anticipated by the
forward-looking statements will occur or, if they do occur, what
benefits the Company will obtain from them. Readers are urged to
consider these factors carefully in evaluating the forward-looking
statements contained in this news release and are cautioned not to
place undue reliance on such forward-looking statements, which are
qualified in their entirety by these cautionary statements. These
forward-looking statements are made as of the date hereof and the
Company disclaims any intent or obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or results or otherwise, except as required by
applicable securities laws.
SOURCE Delta 9 Cannabis Inc.